FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 673 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR American tobacco company Philip Morris International offers £1bn for UK pharma... July 9, 2021 Diagnosed Alone October 6, 2020 FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... November 15, 2022 The Healing Power of Being Outdoors for People With Cancer July 23, 2020 Load more HOT NEWS Health inequalities: “We have a moral duty to reduce them” EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology... Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention...
